References
- Tsang L. Overhauling oversight–European drug legislation. Nat Biotechnol. 2005;23(9):1050–1053.
- DiMartino LD, Curtis LH, Williams RL, et al. Using medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities. Food Drug Law J. 2008;63:891–900.
- Improved guidelines will optimize efficacy and minimize adverse effects of biosimilar drugs. Drugs Ther Perspect. 2008;24:24. doi:10.2165/00042310-200824080-00008.
- Hennessy S, Leonard CE, Platt R; Nature Publishing Group. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States. Clin Pharmacol Ther. 2010;87(2):157–159.
- Reinisch W, Smolen J. Biosimilar safety factors in clinical practice. Semin Arthritis Rheum. 2015;44(6):S9–S15.
- European Parliament. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001. [cited 2016 Jun 24]. Available from: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf.
- Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs. 2011;71(12):1527–1536.
- Casadevall N, Edwards IR, Felix T, et al. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther [Internet]. 2013;13(7):1039–1047.
- Aagaard AW, Purdy S, Philpott S. Review, approval, and marketing of biosimilars in the United States: safety and regulatory issues. Bioprocess Int. 2010;12–20.
- European Medicines Agency. Guideline on similar biological medicinal products. Committee for Medicinal Products for Human Use; 2014 October. [cited 2017 Mar 2]. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
- European Medicines Agency. Guideline on similar biological medicinal products containing biothecnology-derived proteins as active substance: non-clinical and clinical issues. Committee for Medicinal Products for Human Use; 2013 April. [cited 2017 Mar 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
- European Medicines Agency. Guideline on similar biological medicinal products containing biothecnology-derived proteins as active substance: quality issues. Committee for medicinal products for human use. April 2012. [cited 2017 Mar 2]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf
- Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product. Guidance for industry; 2017 January. [cited 2017 Mar 2]. Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm537135.pdf
- Blackstone EA, Fuhr JP. Innovation and competition: will biosimilars succeed?. Biotechnol Healthc. 2012;9(1):24–27.
- Bonilla JW, Beaver N. The New US biosimilar legislation, one year later. Bioprocess Int. 2011;9(5):22–30.
- Genazzani AA, Biggio G, Caputi AP, et al. Biosimilar drugs: concerns and opportunities. BioDrugs. 2007;21(6):351–356.
- Heinemann L, Hompesch M. Biosimilar insulins: how similar is similar? J Diabetes Sci Technol. 2011;5(3):741–754.
- Vulto AG, Crow SA. Risk management of biosimilars in oncology: each medicine is a work in progress. Target Oncol. 2012;7(Suppl. S1):43–49.
- Dowlat HA. The current status of biosimilar biologics. Part 2: practical considerations in international development through European lessons learned. Regul Rapporteur. 2010;7:10.
- Joshi SR. Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India. 2011;59(Suppl):44–47.
- European Parliament. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010. [cited 2016 Jun 24]. Available from: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf
- European Parliament. Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010. [cited 2016 bJun 24]. Available from: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2010_1235/reg_2010_1235_en.pdf
- European Parliament. Commission implementing regulation (EU) No 520/2012 of 19 June 2012. [cited 2016 Jun 24]. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF
- European Parliament. Directive 2012/26/EU of the European Parliament and of the Council of 25 October 2012. [ cited 2016 Jun 24]. Available from: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2012_26/dir_2012_26_en.pdf
- European Parliament. Commission delegated regulation (EU) No 357/2014 of 3 February 2014. [cited 2016 Jun 24]. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0357
- European Parliament. Commission delegated regulation (EU) 2016/161 of 2 October 2015. [ cited 2016 Jun 24]. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2016_161/reg_2016_161_en.pdf
- Assembleia da República. Lei nº 52/2014 de 25 de agosto; [cited 2016 Jun 24]. Available from: http://www.sg.min-saude.pt/NR/rdonlyres/A110CE46-A607-4BD1-AB82-BE86B31314C3/39599/lei52_2014.pdf
- Power DA, Ford D. Biological drugs and the coming of biosimilars. J Pharm Pract Res. 2008;38(2):137–139.
- DiCicco RL. Is Europe ahead of the USA in biosimilars? J Generic Med. 2006;3(3):201–208.
- Choy E, Allen Jacobs I. Biosimilar safety considerations in clinical practice. Semin Oncol. 2014;41(Suppl. 1):S3–S14.
- Khraishi M, Stead D, Lukas M, et al. Biosimilars: a multidisciplinary perspective. Clin Ther. 2016;38(5):1238–1249.
- Zelenetz AD, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. JNCCN J Natl Compr Cancer Netw. 2011;9((Suppl):4.
- Cutroneo PM, Isgrò V, Russo A, et al. Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database. Drug Saf. 2014;37(11):961–970.
- Dowlat HA. Perceptions and realities of clinical safety of biosimilars – EU and US perspectives: part 1. Regul Rapporteur. 2012;9(4):20–25.
- Li EC, Abbas R, Jacobs IA, et al. Considerations in the early development of biosimilar products. Drug Discov Today. 2015;20(S2):1–9.
- Ruiz S, Calvo G; Nature Publishing Group. Similar biological medicinal products: lessons learned and challenges ahead. J Generic Med Bus J Generic Med Sect. 2011;8(1):4–13.
- Dammacco F, Abbracchio MP, Gesualdo L, et al. Biosimilars and safety issues. Leuk Lymphoma. 2009;50(4):656–658.
- Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy. 2005;25(7):954–962.
- Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant. 2006;21(Suppl. 5):v13–6.
- Dowlat HA. Perceptions and realities of clinical safety of biosimilars – EU and US perspectives: part 2. Regul Rapporteur. 2012;9(5):16–19.
- Yamaguchi T, Arato T. Quality, safety and efficacy of follow-on biologics in Japan. Biologicals. 2011;39(5):328–332.
- Macdonald JC, Hartman H, Jacobs IA. Regulatory considerations in oncologic biosimilar drug development. MAbs. 2015;7(4):653–661.
- Young KE, Rémuzat C, Urbinati D, et al. Boosting biosimilars uptake in European countries. ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, 8-12 Nov, 2014. PHP23.
- Drozd M, Szkultecka-Dębek M, Baran-Lewandowska I. Biosimilar drugs – automatic substitution regulations review. Polish ISPOR chapter’s Therapeutic Programs and Pharmaceutical Care (TPPC) task force report. J Heal Policy Outcomes Res. 2014;1:52–57.
- Kurki P, Aets L, Wolff-Holz E, et al. Interchangeability of biosimilars: a European perspective. Bio Drugs. 2017;31:83–91.
- Danish Medicines Agency. Biological and biosimilar medicinal products. [cited 2016 Jun 24]. Available from: https://laegemiddelstyrelsen.dk/en/sideeffects/biological-and-biosimilar-medicinal-products
- Garcia A, Hernandez G, Avendaño S. Regulación de los medicamentos genéricos : evidencias y mitos. Inf Ter Sist Nac Salud. 2010;34(3):71–82.
- Sociedade Espanhola de Farmacologia Clínica. Posicionamento sobre identificación, intercambiabilidad y sustitución de medicamentos biosimilares. 2015. [cited 2016 Jun 24]. Availabvle from: http://www.actasanitaria.com/wp-content/uploads/2015/09/sefc.pdf
- Real Decreto 1718/2010 de 17 de dezembro. [cited 2016 Jun 24]. Available from: http://www.seg-social.es/Internet_1/Normativa/index.htm?dDocName=143907&C1=1001&C2=2010&C3=3027&C4=4002
- FIMEA. Interchangeability of biosimilars – Position of finnish medicines agency Fimea. 2015. [cited 2016 Jul 30]. Availabe from:https://www.fimea.fi/documents/542809/838272/29197_Biosimilaarien_vaihtokelpoisuus_EN.pdf.
- Pasina L, Casadei G, Nobili A. Biological agentes and biosimilars: essentialinformation for the internist. Eur J Intern Med. 2016;33:28–35.
- Declerck PJ. Biotherapeutics in the era of biosimilars.What really matters is patient safety. Drug Saf. 2007;30(12):1087–1092.
- CBG. Medicines Evaluation board. MEB stance on prescribing “biosimilars”; [cited 2016 Jun 24]. Availabe from: http://english.cbg-meb.nl/latest/news/2015/03/31/meb-stance-on-prescribing-%E2%80%9Cbiosimilars%E2%80%9D
- CBG. Medicines Evaluation board. Clarification of stance on biological and biossimilar medicines; [cited 2016 Jun 24]. Available from: http://english.cbg-meb.nl/latest/news/2015/08/17/clarification-of-stance-on-biological-and-biosimilar-medicines
- Direção Geral da Saúde. Norma da Direção Geral de Saúde. Centro Prescritor de Agentes Biológicos; 2014. [cited 2016 Jun 24]. Available from: https://www.dgs.pt/ms/8/pagina.aspx?js=0&codigoms=5521&codigono=02080254AAAAAAAAAAAAAAAA
- Infarmed. Orientações da Comissão Nacional de Farmácia e Terapêutica. Biossimilares. 2016. [cited 2016 Jun 24]. Available from: http://www.infarmed.pt/documents/15786/1816213/1_Orienta%C3%A7%C3%B5es_CNFT_Completa_Final.pdf/bd4475fc-147b-4254-a546-03b8cd63efff
- Thijs J, Giezen TJ, Mantel-Teeuwisse AK, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300(16):1887–1896.
- World Health Organization. Biological Qualifier. An INN Proposal. Programme on International Nonproprietary Names (INN) INN Working Doc. 14.342 Revised draft July 2014. [cited 2016 Jun 24]. Available from: http://www.who.int/medicines/services/inn/bq_innproposal201407.pdf
- Castle GH, Kelly B. Global harmonization is not all that global: divergenteapproaches in drug safety. Food & Drug L.J. 2008;63:601–622.
- Barnes HJ, Ragnarsson G, Alván G. Quality and safety considerations for recombinant biological medicines: a regulatory perspective. Int J Risk Saf Med. 2009;21(1–2):13–22.
- Chamberlain P, Mire-Sluis A. Constructing an immunogenicity risk assessment for follow-on biologics. J Generic Med. 2005;2(2):133–144.
- Ferro H, Donato H, Valtuille R, et al. Worldwile pharmacovigilance of a biossimilar product containing Epoietin. Drug Saf. 2008;31(10):885–960.
- Zemkova M, Jebavy L, Kotlarova J, et al. The spectrum and types of adverse side effects to biological immune modulators: a proposal for new classification. Folia Biol (Praha). 2007;53(4):146–155.
- Berthet-Maillols E. Biosimilars: the reasons to be confident. STP Pharma Prat. 2008;18(6):541–567.